RxDoctor Payments Data

Manila Zaman, MD

Interventional Cardiology · Murrieta, CANPI 1205861770

Payments from drug & device makers

$2,309in general payments, 2019–2025

Across 148 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$459
  • Amgen$413
  • Abiomed$313
  • Novartis$148
  • Boehringer Ingelheim$117
  • Johnson & Johnson$113
  • plus $747 from 16 others

What the payments were for

  • Food & beverage$2,29199%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,309 in reported general payments places this provider in the 20th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$310,992
Medicare patients
446
Services billed
2,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$143,294
XareltoRivaroxaban27$35,865
Repatha SureclickEvolocumab38$31,789
FarxigaDapagliflozin Propanediol31$30,985
BrilintaTicagrelor34$22,225
Repatha SyringeEvolocumab23$16,948
JardianceEmpagliflozin14$16,148
Omega-3 Acid Ethyl Esters33$4,388
Metoprolol Succinate205$3,251
Atorvastatin Calcium293$3,153
Ezetimibe105$2,989
Losartan Potassium191$2,192
ClopidogrelClopidogrel Bisulfate125$1,975
Amlodipine Besylate175$1,257
Hydralazine Hcl77$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$143,294160 claims
AstraZenecaFarxiga, Brilinta$22$53,20965 claims
Johnson & JohnsonXarelto$113$35,86527 claims
Boehringer IngelheimJardiance$117$16,14814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →